Learn more about the role of dual bronchodilator, long-acting β2-agonist (LABA) and long-acting muscarinic antagonist (LAMA), in chronic obstructive pulmonary disease (COPD) based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report (i.e., version 2024) and how to improve clinical outcome in COPD through selection of inhaler device.

CME accredited since 27 December 2023

Learn more about the treatment paradigm for chronic obstructive pulmonary disease (COPD) based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report (i.e. version 2023) and the changes in COPD management over the last decades.

CME accredited until 24 September 2024

In the phase 3 BOREAS trial, dupilumab has demonstrated significant risk reduction in acute exacerbations, improved lung functions and quality of life (QoL) among patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation.1 According to Professor Surya Bhatt, a principal inve

Learn more about the new modifications of the GOLD Report (i.e. version 2023) of COPD management regarding individualized treatment and overprescribing ICS in patients with COPD.

CME accredited until 3 August 2024

    Inhaled corticosteroids (ICS) have been commonly utilized to manage chronic obstructive pulmonary disease (COPD) for decades. Yet the latest evidence has revealed that ICS did not benefit the majority of COPD patients. Therefore, its role in COPD management should be re-evaluated. To minim

Learn more about the specific needs of elderly COPD patients and the latest updates of the international COPD guidelines for their recommendations on the uses of LAMA/LABA dual therapy and eligibilities for ICS among these patients.